NCT00496509已完成1 期
A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases
Genzyme, a Sanofi Company1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2006年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.
研究概览
简要总结
A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed metastatic colorectal adenocarcinoma (stage IV) with at least 1 measurable hepatic lesion of 20 mm or more on MRI and for whom no standard therapy is available.
- •WHO Performance status 0 -
- •Life expectancy of at least 12 weeks
排除标准
- •Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry and stable without steroid treatment for 10 days or greater.
- •Last dose of prior chemotherapy must be discontinued at least 4 weeks before the start of study treatment.
- •Last dose of radiotherapy received within 4 weeks before the start of study treatment excluding palliative radiotherapy.
- •Prior treatment with VEGFR TKIs
- •Serum bilirubin . 1.5 x the upper limit of reference range.
- •Serum creatinine >1.5 x ULRR or Creatinine clearance (as determined by the Cockcroft - Gault method) less than or equal to 50 mL/min.
- •ALT or AST >5 x ULRR
- •ALP >5 x ULRR
- •Evidence of severe or uncontrolled systemic disease or any concurrent conditions which in the investigators opinion make it undesirable for the patient to participate in the study or would jeopardize compliance with the protocol.
- •Any unresolved toxicity greater than CTCAE Grade 2 for previous anti-cancer therapy.
- •Significant cardiovascular event within 3 months before entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia.
- •History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled by medication is not excluded.
- •Congenital long QT syndrome or 1st degree relative with sudden unexplained death under of 40 years of age.
- •Presence of Left Bundle Branch Block.
- •QTc with Bazett's correction unmeasurable or greater than or equal to 480 msec or greater of screening ECG.
- •Potassium <4.0 mmol/L despite supplementation, serum calcium (ionized or adjusted for albumin), or magnesium out of normal range despite supplementation.
- •Women who are pregnant or breast feeding.
- •Any concomitant medications that may cause QTc prolongation or induce or induce Torsades de Pointes or induce CTP3A4 function.
- •Hypotension not controlled by medical therapy.
- •Participation in a clinical study of any investigational pharmaceutical agent within 30 days prior to commencing study treatment.
- •Major surgery within 4 weeks or incompletely healed surgical incision.
- •Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or Squamous cell carcinoma of the skin.
- •Any contraindications to MRI scans.
- •Involvement in the planning or conduct of the study.
- •Previous enrollment or randomization of treatment in the present study.
研究组 & 干预措施
ZD6474 (vandetanib) 100mg
Experimental
干预措施: ZD6474 (Zactima) 100mg (Drug)
ZD6474 (vandetanib) 100mg
Experimental
干预措施: Biomarker Draws (Procedure)
ZD6474 (vandetanib) 100mg
Experimental
干预措施: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) (Procedure)
ZD6474 (vandetanib) 300mg
Experimental
干预措施: Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) (Procedure)
ZD6474 (vandetanib) 300mg
Experimental
干预措施: Biomarker Draws (Procedure)
ZD6474 (vandetanib) 300mg
Experimental
干预措施: ZD6474 (Zactima) 300mg (Drug)
结局指标
主要结局
Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.
时间窗: Up to 57 days.
次要结局
- Determine the population PK of ZD6474 and assess the relationship between both free and total plasma PK and measures of Pharmacological activity(Predetermined timepoints after dose administration)
- Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.(Every 8 weeks during the study)
- Assessment of appropriate Pharmacokinetic parameters(Predetermined timepoints after dose administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I FOLFOX CombinationAdvanced Colorectal CarcinomaNCT00499850Genzyme, a Sanofi Company18
已完成
1 期
Phase I Irinotecan, 5-Fluorouracil and Leucovorin CombinationMetastaticColorectalAdenocarcinomaNCT00507091Genzyme, a Sanofi Company24
已完成
2 期
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in PatientsColorectal CancerNCT00454116Genzyme, a Sanofi Company106
终止
1 期
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal ImpairmentHeart Failure With Reduced Ejection Fraction (HFrEF)Renal ImpairmentNCT06611423AstraZeneca10
已完成
2 期
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLCLung CancerNCT00410189M.D. Anderson Cancer Center54